• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Florence Acquires Virtual Care Solution Zipnosis

Share:

May 29, 2023

Healthcare enablement software company Florence has announced its acquisition of Zipnosis, a virtual care solution focused on asynchronous telemedicine. This acquisition will expand Florence’s product offerings to include both synchronous and asynchronous virtual care, allowing them to create a consumer-centric interface that engages patients throughout their healthcare journey. The addition of Zipnosis’ intelligent adaptive interviews will enhance patient accessibility and free up provider time, enabling clinicians to treat more patients efficiently. Florence aims to address clinical capacity constraints and enable omnichannel transformation across telehealth and hybrid care settings.

What You Should Know:

  • Florence, an innovator in healthcare enablement software, announced today its acquisition of Zipnosis, an asynchronous-first virtual care solution that creates efficiency for clinicians while making quality care more accessible and affordable for patients.
  • Through this acquisition, Florence will broaden its product offerings with synchronous and asynchronous virtual care and further their mission to create a consumer-centric interface that engages patients at every stage of their journey across virtual and physical care to solve healthcare’s most significant constraint: clinical capacity.

Solving Clinical Capacity Constraints and Creating Omnichannel Transformation Across Telehealth and Hybrid Care

“Zipnosis’ asynchronous telemedicine solution is the best in the industry and perfectly aligns with Florence’s vision to create capacity to care in physical settings,” said Aniq Rahman, CEO of Florence. “Together, we’ll create exceptional healthcare experiences for patients virtually and in-clinic while freeing up time for clinicians to focus on what they do best, care for patients.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Adding to Florence’s already robust platform, Zipnosis boosts patient accessibility and frees up 99% of provider work time by using intelligent adaptive interviews that enable care delivery in just 89 seconds. As a result, physicians are able to treat more patients while allocating additional time to those with greater needs. Zipnosis has facilitated 4.5 million patient encounters and engaged 3,500 physicians at over 50 different top health institutions.

The acquisition follows Florence’s formal launch last month, at which time the company announced $20 million in seed funding led by Thrive Capital, GV (Google Ventures), and Salesforce Ventures. With Florence, patients benefit from an experience that rivals consumer-focused industries with the ability to track and accelerate their healthcare journey via smartphone, update clinical information, facilitate prescription fulfillment, initiate self-discharge and schedule follow-up appointments. Florence is dedicated to developing products across multiple sites of care to boost patient satisfaction, increase clinical capacity and reduce rates of patients leaving without being seen by enabling health systems to create omnichannel transformation across telehealth and hybrid care in sites like the emergency room and beyond.

Source: HitConsultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Can artificial intelligence give us a more efficient health care system?Can artificial intelligence give us a more efficient health care system?
  • Marmon Acquires Majority Interest in Colson Medical CompaniesMarmon Acquires Majority Interest in Colson Medical Companies
  • Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion PharmaceuticalsArcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
  • Foamix Pharm And Menlo Therapeutics To Merge – Quick FactsFoamix Pharm And Menlo Therapeutics To Merge – Quick Facts
  • Congress Eyes Another Shot at Telehealth for SNFs with RUSH Act ReturnCongress Eyes Another Shot at Telehealth for SNFs with RUSH Act Return
  • RadNet to Acquire DeepHealth, Inc., Expanding its Efforts in Artificial IntelligenceRadNet to Acquire DeepHealth, Inc., Expanding its Efforts in Artificial Intelligence
  • Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies
  • Health Canada Authorizes POLIVY® (polatuzumab vedotin for injection) for the First-Line Treatment of Adults With Large B-Cell LymphomaHealth Canada Authorizes POLIVY® (polatuzumab vedotin for injection) for the First-Line Treatment of Adults With Large B-Cell Lymphoma

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications